Cogent Biosciences Inc (COGT) Stock Analysis
Verdict: WATCH (do not buy)
FDA NDA acceptance for bezuclastinib validates late-stage pipeline, but a $266M annual FCF burn limits cash runway to ~14 months.
Investment score: 47/100
Analysis as of
Is Cogent Biosciences Inc stock worth reviewing? The TradeMates thesis
The model maintains a HOLD evaluation on Cogent Biosciences Inc (COGT). FDA NDA acceptance for bezuclastinib provides key catalyst visibility, but substantial cash burn ($266.00M USD in 2025) and a $5.65B USD market capitalization constrain near-term risk-adjusted expansion.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 45/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Cogent Biosciences Inc opportunities and risks
What speaks for COGT
- FDA Acceptance of bezuclastinib NDA in AdvSM
What speaks against COGT
- Limited Cash Runway of ~14 Months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| COGT | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.6% |
| MIRM | n/a | 9.6x | n/a | 81.7% | -139.2% | -7.7% |
| ORKA | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.8% |
| SRRK | n/a | 0.0x | n/a | 0.0% | 0.0% | -5.0% |
| TVTX | n/a | 10.0x | 4146.6x | 94.4% | -7.4% | 0.9% |
| DNTH | n/a | 3010.9x | n/a | 96.0% | -1570.9% | -2.7% |
| Peer median | n/a | 9.6x | n/a | 81.7% | -7.4% | -2.7% |
Frequently asked questions about Cogent Biosciences Inc (COGT)
Is COGT stock a good investment?
The TradeMates model rates Cogent Biosciences Inc as WATCH (do not buy) with an investment score of 47/100. The model maintains a HOLD evaluation on Cogent Biosciences Inc (COGT). FDA NDA acceptance for bezuclastinib provides key catalyst visibility, but substantial cash burn ($266.00M USD in 2025) and a $5.65B USD market capitalization constrain near-term risk-adjusted expansion. This is algorithmic model output, not personal investment advice.
Is COGT stock a buy?
The TradeMates model verdict for COGT is WATCH (do not buy) with an investment score of 47/100. Treat this as a model signal to review, not a personal buy recommendation.